MGX
Metagenomi Therapeutics, Inc.
Key Financials
Revenue
$25.2M
↓ 51.8%
Operating Income
$-96013000
↓ 8.0%
Net Income
$-87868000
↓ 12.6%
EPS (Diluted)
$-2.36
0.0%
Total Liabilities
$62.5M
↓ 30.3%
Cash & Equivalents
$41.7M
↑ 52.3%
Shareholders' Equity
$158.6M
↓ 32.5%
Total Assets
$221.1M
↓ 31.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 4/3/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| S-8 | 3/5/2026 | View on SEC |
| 10-K | 3/5/2026 | View on SEC |
| 8-K | 3/5/2026 | View on SEC |
| 8-K | 1/12/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | MGX |
| Company Name | Metagenomi Therapeutics, Inc. |
| CIK | 1785279 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company Emerging growth company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| Phone | (510) 871-4880 |